Clinical trials: Treatment Resistant Major Depressive Disorder
Depression, Neurofeedback
Neurofeedback In Treatment Resistant Depression
The investigators evaluate the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04078438
- Testing
- neurofeedback augmentation, treatment as usual
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Yeungnam University Hospital
Major Depressive Disorder, Depression
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD).
- Conditions
- Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders
- Trial name
- PSI-1V2 (NCT06341426)
- Testing
- Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin
- Where
- 2 sites in Canada
- Volunteers
- 92 people
- Sponsor
- University Health Network, Toronto
Major Depressive Disorder, Treatment Resistant Depression
Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation
Major depressive disorder (MDD) is a complex and severe mental illness, characterized by multiple symptoms, and is a leading cause of non-fatal health loss.
- Trial name
- NCT06542094
- Testing
- Deep Brain stimulation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- West China Hospital
Treatment Resistant Depression, Major Depressive Disorder
Mechanistic Evaluation of Response in TRD (MERIT)
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in…
- Trial name
- MERIT (NCT04608396)
- Testing
- AXS-05
- Where
- 20 sites in United States
- Volunteers
- 44 people
- Sponsor
- Axsome Therapeutics, Inc.
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Depressive Disorder, Major
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression
The goals of this study are: 1) to investigate the efficacy of combining ketamine with intensive cognitive behavioral therapy (CBT) to sustain the antidepressant effects of ketamine; and 2) to determine ketamine's delayed effects…
- Trial name
- NCT03027362
- Testing
- Cognitive behavioral therapy (CBT) and medication, Psychoeducation and medication
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
RESISTance Exercise for Depression Trial
Depression is a leading cause of disability worldwide and current treatments are ineffective for many people. This trial will investigate the efficacy of a 16-week high vs low dose resistance exercise training program for the…
- Trial name
- RESIST (NCT06110897)
- Testing
- High Dose Resistance Exercise Training, Low Dose Resistance Exercise Training Group
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Wisconsin, Madison
Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation in Pharmaco-naïve Patients With Major Depression
Repetitive transcranial magnetic stimulation (rTMS) has become a safe and efficacious treatment for patients with treatment-resistant depression.
- Trial name
- NAIV (NCT04000022)
- Testing
- intermittent theta burst stimulation (iTBS)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital, Bonn
Major Depressive Disorder, Treatment Resistant Depression
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression
This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual.
- Trial name
- NCT07528157
- Testing
- Personalized iTBS, Non-Personalized iTBS
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Stanford University
Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality…
- Conditions
- Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder, Treatment-resistant Bipolar Depression, Major Depressive Disorder (MDD)
- Trial name
- KET-DBT (NCT07569198)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Joshua Rosenblat
Treatment Resistant Major Depressive Disorder
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
To examine the efficacy of Almond Therapy compared to Treatment as Usual when used in addition to an approved version of intranasal esketamine.
- Trial name
- ZYL-730-01 (NCT05323019)
- Testing
- Psychotherapy, Treatment as Usual, Intranasal Ketamine (esketamine)
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Zylorion Health
Depression - Major Depressive Disorder
Effect of Neurofeedback and TMS
The goal of this clinical trial is to is to learn whether adding EEG neurofeedback (NFB) to repetitive transcranial magnetic stimulation (rTMS) is safe and feasible for adults with major depressive disorder (MDD).
- Trial name
- NCT07892287
- Testing
- Repetitive Transcranial Magnetic Stimulation, Alpha-down EEG Neurofeedback
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Treatment-Resistant
Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation
The main purpose of this study is to investigate the two different intermittent Theta Burst (iTBS) repetitive transcranial magnetic stimulation (rTMS), its effectiveness in alleviating depressive symptoms.
- Trial name
- iTBS (NCT05390593)
- Testing
- iTBS-1800, iTBS-1200
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Chang Gung Memorial Hospital
Depressive Disorder
Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients
Phase III, open label, randomised, multicentre, blind for evaluators clinical trial to evaluate the efficacy of esketamine nasal spray at flexible dosis compared to aripiprazole in elderly participants (>60 years) who suffer from…
- Trial name
- CESAR (NCT07153406)
- Testing
- Experimental regimen, Control regimen
- Where
- 9 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Major Depressive Disorder
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
The overarching goal of the present study is to evaluate the effect of a subanesthetic dose of ketamine 24-hour post-injection on resting state functional connectivity, cognitive control, and reward learning.
- Trial name
- NCT04239963
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated.
- Trial name
- NCT01582945
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Major Depression
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S.
- Trial name
- PIVOT (NCT07226232)
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 240 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
NESBID: Neuro-Stimulation of the Brain in Depression
In Canada, approximately 20% of patients with Major Depressive Disorder (MDD) have treatment-resistance and fail to respond to trials of pharmacotherapy or psychotherapy.
- Conditions
- Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Transcranial Direct Current Stimulation, Electric Stimulation Therapy
- Trial name
- NESBID (NCT04159012)
- Testing
- Transcranial direct current stimulation
- Where
- Canada
- Sponsor
- University of Alberta
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
One-Day cTBS Over the Precuneus
The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression.
- Conditions
- Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
- Trial name
- OcTOPUS (NCT07758010)
- Testing
- Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Mclean Hospital